Russia hails Lancet review of early-stage trials of Sputnik-V Covid-19 vaccine

2020-09-04 04:59:00 PM

Russia hails Lancet review of early-stage trials of Sputnik-V Covid-19 vaccine

Russia hails Lancet review of early-stage trials of Sputnik-V Covid-19 vaccine

Russia licensed the two-shot vaccine for domestic use in August and before any data had been published or a large-scale trial begun

Moscow — Russia's “Sputnik-V” Covid-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.“The two 42-day trials — including 38 healthy adults each — did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” The Lancet said.

But with the results now published for the first time in an international peer-reviewed journal, and with a 40,000-strong later-stage trial launched last week, a senior Russian official said Moscow had faced down its critics abroad.Dmitriev said at least 3,000 people had already been recruited for the large-scale trial of the Sputnik-V vaccine launched last week, and initial results were expected in October or November this year.

Read more: Business Day »

Two Gauteng pupils headed for Russia maths OlympiadThe two 17-year-old grade 12 pupils, Kgaogelo Bopape from Horizon International School in Turffontein, and Andi Qu from St John’s College in Houghton, Johannesburg, said they were excited to make it this far in the Olympiads. YoliswaSobuwa

Russia asks Germany for copious details of poison tests on NavalnyRussia has asked Germany to provide exhaustive details of medical tests conducted on Alexei Navalny, a Russian opposition politician lying in a coma in Berlin after a suspected poisoning in Siberia last month, a newspaper reported on Wednesday.

White House 'deeply troubled', UK wants Russia to 'explain' Navalny poisoningThe comments came after doctors treating Navalny in Berlin said the critic of Vladimir Putin was poisoned with a Novichok nerve agent.

Russia jails Jehovah’s Witness duo for ’extremism’extremist'' organisation in 2017 and ordered it to disband. Since then the authorities have detained dozens of Jehovah's Witnesses and convicted them on extremism charges.

COVID-19: Africa CDC urges all nations to join WHO’s COVAX vaccine initiativeNAIROBI, Sept 3 (Reuters) - All nations should join hands in a global effort to procure and distribute potential vaccines against the coronavirus across the globe, the head of Africa's diseases control body said on Thursday.

What is the best way to share out a future COVID-19 vaccine?An international group of ethicists on Thursday criticised the World Health Organisation's goal of distributing coronavirus vaccines to treat 20 percent of each country's population, proposing instead what they said was a more equitable system of distribution.

04 September 2020 - 15:49 Polina Ivanova and Andrew Osborn Picture: 123RF/DAVID IZQUIERDO ROGER Moscow — Russia's “Sputnik-V” Covid-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published on Friday by The Lancet medical journal that were hailed by Moscow as an answer to its critics.The two 17-year-old grade 12 pupils, Kgaogelo Bopape from Horizon International School in Turffontein, and Andi Qu from St John’s College in Houghton, Johannesburg, said they were excited to make it this far in the Olympiads.1 week ago Navalny was flown last month to the Charite hospital in Berlin, where doctors said he may have been poisoned with a cholinesterase inhibitor, a substance found in nerve toxins such as the one used in the attempted poisoning of a former Russian double agent in England in 2018.WASHINGTON/LONDON – The White House said Wednesday it is "deeply troubled" by confirmation in Germany that Alexei Navalny, one of the rare outspoken critics of President Vladimir Putin, was poisoned in Russia.

The results of the two trials, conducted in June-July and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said. Russia licensed the two-shot jab for domestic use in August, the first country to do so and before any data had been published or a large-scale trial begun.. “The two 42-day trials — including 38 healthy adults each — did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” The Lancet said. Navalny, including heavy metals?" asked the letter, which was posted in full on RBC's website. “Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing Covid-19 infection,” it said. If you have already registered or subscribed, please sign in to continue. The vaccine is named Sputnik-V in homage to the world's first satellite, launched by the Soviet Union. "We have seen first-hand the deadly consequences of Novichok in the UK," Johnson said on Twitter, shortly after Germany said Navalny had been poisoned with the highly toxic Soviet-era chemical.

Some Western experts have warned against its use until all internationally approved testing and regulatory steps have been taken. Navalny's biological specimens from the group of cholinesterase inhibitors? Which ones, exactly?" It posed a series of other detailed questions, including: - What medicines were being used to treat Navalny, and in what doses - Whether his condition had worsened, and why - What were the results of tests on his heart and respiratory and central nervous systems. But with the results now published for the first time in an international peer-reviewed journal, and with a 40,000-strong later-stage trial launched last week, a senior Russian official said Moscow had faced down its critics abroad. “With this [publication] we answer all of the questions of that were diligently asked over the past three weeks, frankly with the clear goal of tarnishing the Russian vaccine,” said Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, which has backed the vaccine. “All of the boxes are checked,” he told Reuters. The letter said Russian investigators had meanwhile seized more than 100 items, examined closed-circuit television footage and ordered more than 20 forensic examinations but had so far not uncovered evidence that Navalny had been the victim of a deliberate criminal act. “Now . "The Russian government must now explain what happened to Mr Navalny -- we will work with international partners to ensure justice is done," Johnson said.

.. we will start asking questions of some of the Western vaccines.” Dmitriev said at least 3,000 people had already been recruited for the large-scale trial of the Sputnik-V vaccine launched last week, and initial results were expected in October or November this year. Commenting on the results of the early-stage trials, lead author Dr Naor Bar-Zeev of the International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, USA said the studies were “encouraging but small”. He was initially treated in a local hospital before being flown to Berlin for treatment.

Bar-Zeev, who was not involved in the study, said “clinical efficacy for any Covid-19 vaccine has not yet been shown.” Race to develop vaccine Governments and big pharmaceutical firms are racing to develop a vaccine to end the Covid-19 pandemic, which has killed more than 850,000 people globally and infected around 26-million. More than half a dozen drugmakers are already conducting advanced clinical trials, each with tens of thousands of participants and several, including Britain’s AstraZeneca and US drugmakers Moderna and Pfizer expect to know if their Covid-19 vaccines work and are safe by the end of this year. The Lancet said the early-stage trials suggested the Sputnik-V vaccine produced a response in a component of the immune system known as T-cells. Scientists have been scrutinising the role played by T cells in battling coronavirus infection, with recent findings showing these cells may provide longer-term protection than antibodies. Download the EWN app to your iOS or Android device.

The vaccine, developed by Moscow's Gamaleya Institute, is administered in two doses, with each based on a different vector that normally causes the common cold: human adenoviruses Ad5 and Ad26. Some experts have said that using this delivery mechanism could make a Covid-19 vaccine less effective, since many people have already been exposed to the Ad5 adenovirus and developed immunity to it. In China and the US, about 40% of people have high levels of antibodies from prior Ad5 exposure. In Africa, it could be has high as 80%, experts have said. Denis Logunov, one of the vaccine's developers at the Gamaleya Institute, told Reuters the vaccine uses a strong enough dose of Ad5 to overcome any earlier immunity, without compromising safety.

The booster dose, based on the rarer Ad26 adenovirus, provides further support because the likelihood of widespread immunity to both types in the population is minimal, he said. Russia has said it expects to produce between 1.5-million and two-million doses per month of its potential Covid-19 vaccine by the end of the year, gradually increasing production to six-million doses a month. Reuters .